Highlighting Ongoing Clinical Trials in CML From ASH

EP: 1.How Ponatinib Factors into the Treatment of a Type of Leukemia

EP: 2.The Implications of CML Data From ASH, And Important Takeaways for Providers

Now Viewing

EP: 3.Highlighting Ongoing Clinical Trials in CML From ASH

EP: 4.Phase 3 ASCEMBL Study Demonstrates Superiority of Asciminib in CML-CP

EP: 5.Superiority of Asciminib in CML-CP Is a ‘Win-Win’ for Patients

EP: 6.Asciminib Offers Additional Tool to Treat CML-CP

EP: 7.Ongoing Studies in CML-CP Offer Hope to Future Treatments

EP: 8.Recap: Moffitt and Mayo Face-Off in CML Treatment Updates From ASH

During a post-Face-Off interview, Kendra Sweet, MD, discussed the use of futibatinib (Lytgobi) in patients with chronic myeloid leukemia (CML).

Transcript:

[The trial with futibatinib (Lytgobi)] is ongoing. It’s a small study, with 43 patients who’ve been enrolled, but it is an active drug. That’s a study that's going to be harder to enroll in because the drug doesn’t have activity in T315I. We have a lot of drugs in CML now, and they are all very active drugs. Finding a place to position that drug will be a challenge, but I think it will be interesting to see where that falls in the sequence of all these other agents. Depending on the [adverse] effect profile and the toxicity of that drug, that’s where it could potentially be impactful if it has a tall, tolerable [adverse] effect profile. I think then it could be a valuable drug, but there are a lot more patients that need to be treated with it before we start to move that into any kind of standard of care.